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Purpose: To study the antiangiogenic activity of two small peptides (H-RN and H-FT) derived from the hepatocyte growth
factor kringle 1 domain (HGF K1) using in vitro and in vivo assays.
Methods: RF/6A rhesus macaque choroid-retina endothelial cells were used for in vitro studies. The inhibiting effect of
two peptides on a vascular endothelial growth factor (VEGF)-stimulated cell proliferation, cell migration, and endothelial
cell tube formation were investigated. For in vivo assays, the antiangiogenic activity of H-RN and H-FT in the chick
chorioallantoic  membrane  model  (CAM)  and  a  mice  oxygen-induced  retinopathy  model  (OIR)  were  studied.  A
recombinant mouse VEGF-neutralizing antibody, bevacizumab, and a scrambled peptide were used as two control groups
in separate studies.
Results:  H-RN  effectively  inhibited  VEGF-stimulated  RF/6A  cell  proliferation,  migration,  and  tube  formation  on
Matrigel™, while H-FT did not. H-RN was also able to inhibit angiogenesis when applied to the CAM, and had
antineovascularization  activity  in  the  retinal  neovascularization  of  a  mouse  OIR  model  when  administrated  as  an
intravitreous injection. The antiangiogenic activity of H-RN was not as strong as that of VEGF antibodies. The H-FT and
scrambled peptide had no such activity.
Conclusions: H-RN, a new peptide derived from the HGF K1 domain, was shown to have antiangiogenic activity in vitro
and in vivo. It may lead to new potential drug discoveries and the development of new treatments for pathological retinal
angiogenesis.
There  has  been  rapid  growth  in  diabetes  mellitus
prevalence, and diabetic retinopathy (DR) has become the
leading cause of blindness in adults of working age [1]. With
the survival rate of premature infants increasing, retinopathy
of prematurity (ROP) has become the major cause of blindness
in children under the age of seven [2,3]. Both DR and ROP
are likely to emerge as major public health threats in the near
future. Neovascularization is the critical pathological process
in both of these vascular retinopathies that cause blindness
[4–7]. This pathological change is accompanied by retinal
edema,  blood-retinal  barrier  breakdown,  hemorrhage,
irreversible  tissue  damage,  and  scarring  [8–14].  Laser
photocoagulation is the current established therapy for retinal
neovascularization and is effective in delaying the progression
of the disease. However, it lacks specificity, and causes retinal
destruction,  impaired  visual  function,  and  scotoma  [15].
Photodynamic therapy, which is a relatively newly developed
treatment,  blocks  existing  neovasularization  but  does  not
prevent  pathological  angiogenesis.  Treatments  that
selectively  inhibit  or  block  the  molecular  mediators  of
neovascularization are needed [16].
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Vascular endothelial growth factor (VEGF) is a major
mediator of the angiogenic process. Numerous therapeutic
strategies targeting VEGF are being studied [16,17]. New
therapeutic  agents,  such  as  pegaptanib,  ranibizumab,  and
bevacizumab, have been developed. Some of them have been
approved by the US Food and Drug Administration, and the
others are still in clinical trials [16]. The extremely high annual
drug-treatment cost, however, has limited their wide use, and
systemic adverse events have been reported. For instance,
intravenous bevacizumab can cause hypertension, congestive
heart  failure,  bleeding,  neutropenia,  proteinuria,
thromboembolism,  and  neuropathy  [18,19].  Though
intravitreal  application  might  circumvent  these  adverse
effects,  breakdown  of  the  tight  blood-ocular  barrier  is
common  in  neovascular  eye  diseases  [20],  and  systemic
exposure  is  inevitable.  Other  well  known  angiogenic
inhibitors,  such  as  angiostatin,  endostatin,  and
thrombospondin-1,  are  large,  complex  proteins  and  are
therefore difficult and costly to manufacture [21].
Designing  and  developing  peptides  to  inhibit
angiogenesis  is  an  important  area  of  antiangiogenic  drug
development [21]. Compared to proteins, peptides have lower
immunogenicity, higher solubility in water, stable production
methods, and improved consistency between batches [16,21].
They are also better at targeting and penetrating tumors [22].
Endogenous protein angiogenesis stimulators and inhibitors
have  been  considered,  and  there  is  plenty  of  information
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1982available  for  designing  antiangiogenic  peptides  for  drug
development  [23–28].  Conserved  protein  domains  carry
phylogenetic information, have structural roles, and perform
unique functions; hence, they have always been an important
source  for  designing  antiangiogenic  peptides  [21,25,29].
Antiangiogenic peptides derived from thrombospondin [30],
endostatin [31], decorin [32], tumstatin [33], and histidine-
proline-rich glycoprotein [34], for example, have been widely
reported,  and  some  peptide  drugs  with  antiangiogenic
treatment purposes have entered clinical trials.
Hepatocyte growth factor (HGF) was first discovered to
strongly promote liver cells growth [35]. Subsequently, HGF
was found to play a significant biologic role in health and
disease [36,37]. HGF is a potent stimulator of new vessel
formation  and  an  important  angiogenic  factor  in  vascular
retinopathies, such as proliferative DR and ROP [38–42]. The
mature form of HGF consists of disulphide-linked α- and β-
chains. The α-chain is made up of an N-terminal domain and
four kringle domains (an 80-amino acid triple-loop structure
maintained by three intramolecular disulfide bonds highly
conserved  between  different  kringle-containing  proteins
[43]). The β-chain consists of a single domain that retains the
fold of the catalytically active serine proteinases but has no
enzymatic activity [44]. Though wild-type HGF is itself a
strong angiogenic stimulator, several HGF variants have been
constructed  and  have  been  shown  to  have  antiangiogenic
activity, such as NK4 (composed of the NH2-terminal hairpin
domain and four kringle domains in the α-chain of HGF)
[45,46], kringle 1–4 [47], the N-terminal domain [48], and
kringle 1 [49–51]. Xin et al. [49] first discovered that the
kringle 1 domain of HGF (HGF K1) inhibited endothelial cell
proliferation stimulated by basic fibroblast growth factor, and
that it caused cell apoptosis. It was shown to be three times
stronger  than  angiostatin  in  inhibiting  the  proliferation  of
endothelial cells. HGF K1 was then reported to exhibit both
antiangiogenic and antitumor cell effects [50,51].
Angiogenesis is the formation of new blood vessels from
the  preexisting  vasculature.  This  process  depends  on  the
proliferation, migration, and capillary-like tube formation of
vascular endothelial cells [52]. The HGF K1 domain has been
shown  to  be  an  angiogenesis  inhibitor.  We  chose  two
conserved  sequence  segments  of  the  HGF  K1  domain  to
construct  two  small  peptides,  using  a  solid-phase  peptide
synthesis method [53]. To address the issue of whether the
two  small  peptides  have  antiangiogenic  activity,  we
performed in vitro assays on the choroid-retina endothelial
cell line (RF/6A) and in vivo assays for angiogenesis in the
chorioallantoic membrane (CAM) model and in mice. We
discovered that one of the two peptides inhibited RF/6A cell
proliferation, migration, capillary-like tube formation, and
angiogenesis in the CAM model and in a mouse ROP model
(OIR), while the other peptide did not. The newly discovered
peptide with antiangiogenic activity could likely serve as a
therapeutic peptide drug in vascular retinopathies and other
angiogenic-related diseases, such as tumors.
METHODS
Cell culture and materials: RF/6A cells were obtained from
the American Type Culture Collection and were maintained
as  monolayer  cultures  in  a  culture  medium  consisting  of
RPMI1640  supplemented  with  10%  fetal  bovine  serum
(Gibco, Rockville, MD) at 37 °C in 5% CO2 and 95% ambient
air. The culture medium was changed every 3 days. Human
VEGF165  was  obtained  from  (Sigma-Aldrich,  St.  Louis,
MO). Two conserved amino acid sequences of HGF K1 (H-
RN: RNPRGEEGGPW, molecular weight: 1254.34 Da; H-
FT: FTSNPEVRYEV, molecular weight: 1340.47 Da) and a
scrambled peptide were synthesized by solid-phase peptide
synthesis using an automatic peptide synthesizer (Symphony;
Protein Technologies, Tucson, AZ). The end product was
characterized  by  high-performance  liquid  chromatography
(HPLC;  LC-20A,  Shimadzu,  Kyoto,  Japan)  and  mass
spectrometry (MS; Finnigan TSQ 7000; Thermo, Waltham,
MA). Both of the synthesized peptides were water-soluble.
Stability assay of peptides in aqueous solutions: The stability
of peptides in various aqueous solutions was investigated, as
previously described [54], with slight modification. Briefly,
lyophilized  H-RN,  H-FT  and  scrambled  peptide  were
dissolved in water or in buffer at a concentration of 200 µg/
ml. Buffers included: a) 12.5 mM citrate and 14 mM NaCl pH
6; b) 12.5 mM citrate and 46.2 mM NaCl pH 4; c) Hanks
balanced salt solution (HBSS) pH 6; d) HBSS pH 7.4; e)
phosphate buffered saline (PBS, 0.137 M NaCl, 0.0027M
KCl, 0.01M Na2HPO4, 0.002 M KH2PO4) pH 7.4; and f) BSS
PLUS™ sterile intraocular irrigating solution (Alcon, Inc.;
Hünenberg,  Switzerland).  BSS  PLUS™  is  an  intraocular
irrigating  solution  for  use  during  all  intraocular  surgical
procedures (used to imitate the intraocular condition). The
peptide solutions were incubated at 4 °C or 37 °C for 4, 24, or
48 h, then stored at −80 °C. The solutions without incubation
and immediately frozen at −80 °C were used as controls. The
stability of peptides was evaluated by HPLC. Samples were
thawed at room temperature for 5 min before testing.
Cell  proliferation  assay:  A  cell  proliferation  assay  was
performed as described previously [55,56]. A colorimetric
MTS  (3-(4,5-dimeth-ylthiazol-2-yl)-5-(3-
carboxymethoxyphenol)-2-(4-sulphophenyl)-2H-
tetrazolium) assay (CellTiter 96 AQ; Promega, Madison, WI)
was  used  according  to  the  manufacturer’s  instructions.
Briefly, cells were seeded onto a 96-well plate (4.8×103 cells/
well). After 24 h, cells were serum-starved overnight, and then
treated with 100 ng/ml VEGF and various doses of H-RN or
H-FT (0, 1 μM, 10 μM, 100 μM, or 1 mM) in 100 μl of serum-
free medium for an additional 24 h. In positive control group,
100 μl of serum-free medium contains 100 ng/ml VEGF and
0.25 or 2.5 mg/ml bevacizumab (Avastin®, Hoffmann-La
Roche Ltd., Basel, Switzerland), and the negative control
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concentrations of 1 μM, 10 μM, 100 μM, or 1 mM. After
completion  of  the  treatment,  20  μl  of  the  3-(4,5-
dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenol)-2-(4-
sulphophenyl)-2H-tetrazolium (MTS) reagent were pipetted
into each well and incubated for 4 h. The absorbance at 490
nm was recorded using a microplate reader (Bio-Rad, Model
680,  Hercules,  CA).  Each  group  was  tested  at  least  in
triplicate, and the assays were repeated a minimum of three
times.
Cell migration assay: A cell migration assay was performed
as described previously [57], with modification as below.
Briefly, RF/6A cells were starved overnight, trypsinized, and
suspended at a final concentration of 5×105 cells/ml. Various
concentrations of bevacizumab or peptides were preincubated
with the cells for 30 min at 37 °C before seeding into the
Transwell chambers (pretreated by culture medium, 10 mm
diameter, 8.0 µm pore size; Corning Inc., New York, NY), the
5×104 cells were added to each upper chamber. VEGF (100
ng/ml) was placed into the lower chamber. The assembled
cell-culture insert chamber was then incubated at 37 °C for 24
h.  After  removing  the  nonmigrating  cells  in  the  upper
chambers with a cotton swab, migrated cells on the lower
surface of the porous membrane were fixed, stained with
Gram  stain,  and  photographed  under  a  light  microscope
(Olympus, Tokyo, Japan). Five random fields (×200) were
chosen in each insert, and the cell number was quantified
manually. Each experiment was repeated three times.
Endothelial cell tube formation assay: A tube formation assay
was performed as previously described [58]. The 96 well
culture plate were coated with Matrigel™ (BD Biosciences,
Bedford, MA) according to the manufacturer’s instructions.
RF/6A  cells  (2.5×104  in  number)  were  preincubated  with
various concentrations of bevacizumab or peptides (100 nM–
1 mM) before being seeded on coated plates in a serum-free
medium containing VEGF 100 ng/ml, and then incubated at
37 °C for 6 h. Tube formation was observed using an inverted
phase contrast microscope (Olympus, Tokyo, Japan). Images
were captured with a digital camera (Olympus). The degree
of tube formation was quantified by measuring the length of
tubes in three randomly chosen fields (with magnification of
×100)  from  each  well  using  the  Image-Pro  Plus  Program
(version 5.1; Media Cybernetics, Inc.). Each group was tested
in triplicate. Each experiment was repeated three times.
Chick chorioallantoic membrane assay: A CAM assay was
performed  to  determine  the  antiangiogenic  activity  of  the
peptides.  Briefly,  5  μl  of  0.01  M  PBS  (0.137  M  NaCl,
0.0027M KCl, 0.01M Na2HPO4, 0.002 M KH2PO4, pH 7.4)
containing H-RN, H-FT, or scrambled peptide separately at
concentrations of 0, 2, or 10 μg/μl were loaded onto a 0.5 cm-
diameter Whatman quantitative ﬁlter paper (Sigma-Aldrich),
and the ﬁlter was dried under sterile air. The ﬁlter was then
applied to the CAM of an eight-day embryo. After incubation
for  72  h,  angiogenesis  around  the  test  materials  was
microscopically  evaluated  using  an  Olympus  SZX2-ILLT
stereoscope.  The  number  of  blood  vessels  was  quantified
manually in a circular perimeter surrounding the implants, at
a distance of 0.25 cm from the edge of the filter. Assays for
each test sample were performed twice, and each experiment
contained 10–15 eggs per data point [59]. All analyses were
done with the observer masked as to the study group.
Animal model of proliferative retinopathy: All experiments
were consistent with the ARVO Statement for the Use of
Animals in Ophthalmic and Vision Research. A reproducible
model  of  ischemia-induced  retinal  neovascularization  has
been described in detail [60]. Pregnant female C57BL/6J mice
were obtained from the Shanghai Laboratory Animal Center,
Chinese Academy of Sciences. Each litter contained 7–9 pups;
each group was consisted of 7–9 pups. Briefly, on postnatal
day 7 (P7), litters of C57BL/6J mouse pups with their mothers
were exposed to 75%±2% oxygen (hyperoxia) for 5 days and
then  returned  to  room  air  for  5  days,  producing  retinal
ischemia and neovascularization by P17. Mice of the same age
were kept in room air and used as normal control subjects.
Peptides  were  administered  as  intravitreous  injections  at
concentrations of 10 mM or 50 mM. PBS and anti-mouse
VEGF antibodies (VEGFab, a neutralizing antibody to VEGF
that recognizes the mouse; Sigma-Aldrich) were injected as
controls. PBS and peptide injections were performed twice on
P12 and P14, and a VEGFab injection was given once on P12,
according to Geisen et al. [14]. For the intravitreous injections,
a  topical  anesthetic  (0.4%  oxybuprocaine,  Santen
Pharmaceutical Co., Ltd., Hakui-gun, Ishikawa, Japan) was
administered  before  inserting  a  sterile  30-gauge  needle
posterior to the limbus to avoid lens damage. A 1 µl injection
was performed in the left eyes using a Hamilton syringe.
Topical Ofloxacin ointment (0.3%; Santen Pharmaceutical
Co., Ltd.) was then applied to the injected eye. All the right
eyes  were  not  injected.  Pups  were  then  returned  to  their
mothers in room air for 5 days [14].
At P17, retinal tissue was dissected and flatted, and eye
sections  were  performed.  In  detail,  the  pups  were  deeply
anesthetized intraperitoneally with tribromoethanol (0.2 ml/
10 g bodyweight) and then perfused through the left ventricle
with 4% paraformaldehyde. Both eyes were enucleated and
fixed  in  4%  paraformaldehyde  for  2  h.  The  retinas  were
dissected and flattened. The retinal vasculature was stained
with  Alexa  Fluor  568  conjugated  isolectin  B4  (Molecular
Probes, Eugene, OR) as previously described [14]. Briefly,
the  dissected  retinas  were  permeabilized  in  ice-cold  70%
ethanol for 20 min, then in 1% Triton X−100 for 30 min, and
then incubated with 5 μg/ml isolectin B4 overnight at 4 °C.
Each  retina  was  rinsed  three  times  in  PBS,  mounted  in
PBS:glycerol (2:1) and protected with a coverslip. Isolectin
B4 selectively binds with terminal α-D-galactosyl residues,
and has strong affinity for perivascular cells and endothelial
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an Olympus BX51 upright microscope. For sections, the eyes
were  embedded  in  paraffin  after  being  fixed  with  4%
paraformaldehyde. Serial sections (10 μm) of whole eyes were
cut sagittally, through the cornea and parallel to the optic
nerve,  and  stained  with  hematoxylin  and  eosin.  Vascular
lumens, identified under light microscopy, were considered to
be associated with new vessels if they were found on the
vitreal side of the internal limiting membrane. New vessel
lumens were counted in cross-section with light microscopy
(magnification, 400×) by two masked observers [14]. Each
data point represented a minimum of one eye each from seven
pups. The efﬁcacy of treatment was qualitatively evaluated by
isolectin  B4-stained  flat  mounting  retinal  tissue,  and  was
quantitatively evaluated by comparison of the average number
of neovascular lumens per section in the eyes of peptide-
treated animals and controls [8].
Statistical  analysis:  For  experiments  with  more  than  two
treatment  groups  and  various  treatment  concentrations,
univariate  ANOVA  was  used.  For  comparison  of  the
differences between groups, a post hoc Least-Significance-
Difference (LSD) test was used. All values were expressed as
the  mean±SD.  An  alpha  level  of  <0.05  was  used  as  the
criterion of significance.
RESULTS
Stability of H-RN, H-FT, and scrambled peptide: H-RN, H-
FT, and scrambled peptide were tested in different aqueous
solutions at different temperatures and storage times. The
stability was analyzed as a percentage of the purity of control
solutions. Details are shown in Table 1. Three peptides were
less stable in PBS (pH 7.4, 37 °C), citrate buffer (pH 6, 37 °C),
and BSS PLUS™ (pH 7.4, 37 °C). Some peptide degradation
happened  after  incubation  for  24–48  h.  However,  the
degradation only happened in a small part of the total peptide
content, and more than 90% still existed after 48 h. The three
peptides had high stability under the other six incubation
conditions. From the data in Table 1, we inferred that 4 °C and
TABLE 1. STABILITY OF H-RN, H-FT AND SCRAMBLED PEPTIDE IN DIFFERENT CONDITIONS
 
      Mean±SD percentage of controls
Medium pH Temperature (°C) Time (h) H-RN H-FT Scrambled
peptide
Citrate buffer 6 4 4 99.97±0.02 98.99±0.36 99.85±0.18
      24 99.83±0.19 99.65±0.18 100.02±0.06
      48 99.29±0.31 98.01±0.23 99.73±0.20
PBS 7.4 4 4 99.91±0.37 99.96±0.17 100.03±0.07
      24 99.82±0.39 99.12±0.05 99.68±0.11
      48 100.18±0.31 98.89±0.22 99.65±0.12
PBS 7.4 37 4 100.1±0.23 99.69±0.08 100.12±0.18
      24 99.44±0.09* 98.56±0.12* 99.25±0.16*
      48 97.89±0.48* 98.09±0.13* 98.29±0.29*
H2O 4.7 37 4 99.84±0.04 99.62±0.21 99.43±0.06
      24 99.99±0.06 99.53±0.08 99.32±0.05
      48 99.78±0.19 99.25±0.11 99.28±0.16
Citrate buffer 4 37 4 99.57±0.57 99.42±0.27 100.06±0.05
      24 99.85±0.40 99.35±0.19 99.72±0.13
      48 99.59±0.11 99.13±0.25 99.28±0.21
Citrate buffer 6 37 4 98.97±0.03* 99.86±0.11 99.54±0.15
      24 97.98±0.03* 98.04±0.23* 98.02±0.33*
      48 94.71±0.08* 97.88±0.09* 98.78±0.19*
HBSS 6 37 4 98.82±1.24 100.06±0.08 99.73±0.18
      24 100.15±0.11 99.18±0.23 99.64±0.06
      48 98.60±0.08 99.65±0.09 99.23±0.27
HBSS 7.4 37 4 100.20±0.11 99.93±0.24 99.86±0.15
      24 99.90±0.22 99.67±0.18 100.02±0.07
      48 99.28±0.63 99.25±0.09 99.37±0.21
BSS PLUS™ 7.4 37 4 99.85±0.25 98.61±1.28 98.81±0.35
      24 99.95±0.05 95.22±2.09* 97.44±0.29*
      48 98.12±0.26* 97.53±0.32* 98.01±0.18*
         No statistical differences unless otherwise stated. #Standard deviation;  *p<0.05 (tested condition compared to control).
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stability of these peptides.
RF/6A cell proliferation inhibition by H-RN rather than H-
FT: RF/6A cells were exposed for 24 h to VEGF (100 ng/ml),
or  to  VEGF  combined  with  various  concentrations  of
bevacizumab, H-RN, or H-FT. In comparison to the control
group, VEGF alone induced an increase of cell proliferation
(p<0.05;  Figure  1).  VEGF-induced  cell  proliferation  was
strongly inhibited by 2.5 mg/ml bevacizumab. After adding
different  concentrations  of  peptides,  H-RN  resulted  in  a
significant reduction in cells (p<0.05). At the highest dose of
H-RN tested (1 mM), the mean absorbance value was very
close to that of the control group (0.735 versus 0.673), though
this inhibitory effect was not as strong as that of 2.5 mg/ml
bevacizumab (0.735 versus 0.615). In contrast, in the H-FT
groups, no inhibitory effect on cell proliferation was observed,
even at a millimolar concentration (p>0.05). The scrambled
peptide group showed no inhibitory effect, either (p>0.05;
Figure  1A).  These  data  indicate  that  increasing  H-RN
concentration may be responsible for the impaired RF/6A cell
proliferation in response to VEGF165; H-FT could not inhibit
RF/6A cell proliferation. Another group treated with H-RN
alone was tested to detect whether the high dose of H-RN
might  induce  cell  death  instead  of  inhibition  of  cell
proliferation. As can be observed in Figure 1B, cell viability
was not affected by H-RN at any concentration tested, as
compared to the culture medium group (control).
Figure  1.  H-RN  inhibits  endothelial
cells  (EC)  proliferation  while  H-FT
does not. A: After 24 h of starvation,
rhesus  macaque  choroid-retina
endothelial  (RF/6A)  cells  were
incubated  in  vascular  endothelial
growth  factor  (VEGF)  and  various
concentrations  of  bevacizumab  or
peptides  for  24  h;  RF/6A  cell
proliferation  was  inhibited  by
bevacizumab  and  H-RN.  An  H-RN
concentration  of  1  mM  inhibited  the
VEGF-induced  response  significantly.
However, the inhibitory effect was not
as strong as bevacizumab’s. H-FT and
scrambled  peptide  had  no  inhibitory
activity  on  RF/6A  cells  at  various
concentrations  (**p<0.01,  each
condition versus control). B: Compared
to  the  culture  medium  group,  cell
viability  was  not  affected  by  H-RN
alone  at  any  concentration  tested
(p>0.05, each condition versus control.)
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1986H-RN suppression of VEGF-driven migration: The migration
of RF/6A cells was studied using a Transwell chamber method
by which the endothelial cells migrated through a porous
membrane toward a VEGF stimulus. The inhibitory activity
of various concentrations of H-RN and H-FT (1 nM, 10 nM,
100 nM, 1 µM, and 10 µM) on endothelial cell migration was
studied. Bevacizumab and scrambled peptide were also added
as controls. Compared to the no-VEGF group, the number of
migrated cells in the VEGF group was significantly higher
(p<0.001). The results showed that bevacizumab effectively
inhibited cell migration at both concentrations (p<0.001). H-
RN  inhibited  VEGF-stimulated  endothelial  cell  migration
with an ED50 around 10 nM, whereas H-FT did not inhibit
VEGF-induced cell migration at concentrations from 1 nM to
1 µM. H-FT had only a mild inhibitory effect at the 10 µM
concentration,  and  this  observation  was  not  statistically
significant (p>0.05; Figure 2). The scrambled peptide did not
present any inhibitory effects.
H-RN and H-FT mediation of different inhibitory effects on
endothelium tube formation: The amount of 100 ng/ml of
VEGF  strongly  stimulated  RF/6A  cell  endothelium  tube
formation, compared to the no-VEGF group. Tube formation
was strongly inhibited by bevacizumab at both concentrations.
Similarly, but not as strongly as with bevacizumab, H-RN
inhibited  VEGF-induced  RF/6A  cell  tube  formation  on
Matrigel™ much more potently than did H-FT (Figure 3A-F).
H-RN effectively inhibited tube formation (p<0.001), and its
ED50 was around 100 µM. In contrast, H-FT did not effectively
inhibit VEGF-induced RF/6A cell tube formation (p>0.05;
Figure  3G).  It  is  most  interesting  that  H-FT,  at  a  1  mM
concentration, had a mild inhibitory effect on tube formation,
though it appeared inactive in the cell proliferation assay.
When  experiments  were  repeated,  consistent  results  were
observed.  The  scrambled  peptide  did  not  inhibit  VEGF-
induced  endothelium  tube  formation  at  any  concentration
(p>0.05).
H-RN  inhibition  of  chick  chorioallantoic  membrane
angiogenesis: The CAM results indicated H-RN inhibited
angiogenesis on CAM (Figure 4). In the 10 µg and 50 µg H-
RN  groups,  the  number  of  vessels  decreased  notably
compared to PBS group 4,285 ogenesis on CAM (p<0.001).
However, the H-FT and scrambled peptide presented no such
activity at any concentration (p>0.05; Figure 4). The results
Figure 2. Effects of peptides on the migration of RF/6A cells stimulated by vascular endothelial growth factor. Bevacizumab and peptides
were added in the upper chamber containing RF/6A cells 30 min before the stimulation of vascular endothelial growth factor (VEGF) in the
lower chamber (100 ng/ml). After 24 h of incubation, migratory activity of the cells was estimated. Bevacizumab and H-RN inhibited migration
of RF/6A cells. H-FT and scrambled peptide did not inhibit migration up to 1 µM concentration, whereas at 10 µM there was a mild inhibition
(*p<0.05; **p<0.01, each condition versus control).
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1987Figure 3. Inhibition effects of H-RN and H-FT on endothelial cell differentiation into capillary structures. Starved RF/6A cells were pre-
incubated with different concentrations of bevacizumab, H-RN, and H-FT for 30 min before 100 ng/ml vascular endothelial growth factor
(VEGF) was added in peptides treated and VEGF groups, and then cells were seeded into Matrigel-coated wells. A-F: Representative
photographs of anti-tube formation activity of bevacizumab, H-RN, H-FT, and scrambled peptide: A, no-VEGF; B, 100 ng/ml VEGF; C, 100
ng/ml VEGF +2.5 mg/ml bevacizumab; D, 100 ng/ml VEGF +1 mM H-RN; E, 100 ng/ml VEGF +100 nM H-FT; F, 100 ng/ml VEGF +1
mM scrambled peptide. VEGF at 100 ng/ml strongly stimulated endothelium tube formation. Bevacizumab and H-RN potently inhibited
VEGF-stimulated RF/6A cell tube formation on growth factor-reduced Matrigel™. H-FT and scrambled peptide did not inhibit RF/6A cell
tube formation effectively (magnification ×200). G: Quantitative analysis of tube formation under the different experimental conditions using
Image Program Plus software. The values are mean tube lengths from three repeated experiments (** p<0.01, each condition versus control).
Molecular Vision 2010; 16:1982-1995 <http://www.molvis.org/molvis/v16/a214> © 2010 Molecular Vision
1988demonstrate that H-RN was able to suppress angiogenesis in
chicken embryos.
Effect  on  retinal  neovascularization  of  peptides
administration: For qualitative analysis, retinal ﬂatmounts
were prepared. The vasculature labeled by Alexa Fluor 568-
conjugated isolectin B4 showed that there was no effect of H-
FT  on  the  pathologic  neovascular  tufts  of  the  retinas  of
oxygen-treated mouse pups. In contrast, pathologic retinal
neovascularization was signiﬁcantly inhibited by injection of
VEGFab (at doses of 25 ng/μl or 50 ng/μl) and H-RN (both
10 mM and 50 mM; Figure 5A-F). The neovascular lumens
were deﬁned as the mean number per section found in at least
10 sections per eye. Treatment with 25 ng/µl or 50 ng/µl
VEGFab  resulted  in  a  significant  reduction  in  preretinal
lumens. Though not as remarkable as with VEGFab, injection
of 50 mM H-RN still reduced neovascularization more than
60%,  compared  to  the  PBS  control.  Neither  H-FT  nor
scrambled peptide showed significant reduction of preretinal
lumens when compared to the PBS-injected eye (Figures 5G-
M).
Taken  together,  these  results  suggest  that  H-RN  can
effectively inhibit pathologic retinal neovascularization in a
mouse model of oxygen-induced retinopathy.
DISCUSSION
HGF is a polypeptide structurally related to the enzymes of
the blood coagulation cascade, which has no antiangiogenic
activity, but is a growth factor with angiogenic activity [48].
However, HGF K1 has been shown to be able to suppress
tumor angiogenesis in hepatocyte cancer and colon cancer
[50,51]. Due to peptides’ small size, simplicity of synthesis,
lack of toxicity, immune reaction to the host system, and
receptivity to chemical modification, they have been widely
developed  for  the  medication  of  tumors  and  other
angiogenesis-related diseases. In this study, we synthesized
two peptides derived from a conserved sequence of HGF K1
to investigate their potential antiangiogenic activity. It is well
known that VEGF is often viewed as the gold standard of
angiogenic factors. It is the most important angiogenic factor
to induce endothelial cell proliferation, migration, and tube
formation [61]. This is the reason we chose VEGF as the
negative control in the in vitro studies.
Bevacizumab  is  a  complete,  humanized  monoclonal
antibody directed against all isoforms of VEGF. It was ﬁrst
approved by the US Food and Drug Administration as a ﬁrst-
line treatment for metastatic colorectal cancer. Recently, the
application  of  intravitreal  bevacizumab  for  the  effective
antiangiogenic  treatment  of  retinal  and  choroidal
neovascularization has been widely reported. [62]. In this
study, we chose bevacizumab as a positive control in the in
vitro studies.
Although various HGF variants have been reported to
inhibit in vitro and in vivo angiogenesis, we showed here for
the first time that a peptide derived from HGF can inhibit
VEGF-induced in vitro and in vivo angiogenesis. H-RN and
H-FT have the same length of amino acid sequences; however,
they  have  significantly  different  biologic  effects  on
angiogenesis.  We  demonstrated  that  H-RN  effectively
inhibited  VEGF-induced  choroid-retinal  endothelial  cell
proliferation, migration, and tube formation, as well as in vivo
angiogenesis in CAM and OIR in C57BL/6J mice. H-FT and
scrambled peptide had no such effects. In the in vitro studies,
H-RN exhibited more potency in inhibiting endothelial cell
migration  than  inhibiting  cell  proliferation  and  tube
formation; the effective concentrations were much lower than
those in the migration and tube formation assays. Perhaps
inhibiting  endothelial  cell  migration  is  one  of  the  critical
mechanisms of H-RN antiangiogenesis activity.
Xin et al. [49] first reported in 2000 that kringle 1 of HGF
effectively  inhibited  endothelial  cell  proliferation.  In
subsequent  studies,  they  showed  that  the  same  kringle
structure could also inhibit endothelial cells’ capillary-like
tube formation, tumor angiogenesis, and tumor growth [50].
Kringle 1 of HGF is the mother domain of the peptides in our
present  study,  and  although  H-RN  has  no  such  strong
antiproliferative effect, it can effectively inhibit endothelial
cell  migration,  tube  formation,  and  angiogenesis  in  vivo.
Hence, the sequence of H-RN studied might be a part of the
critically  active  sequence  of  HGF  kringle  1  in
antiangiogenesis.
Mayo  et  al.  [63]  reported  that  aliphatic  hydrophobic
residues are commonly seen in peptides with antiangiogenic
activity, and these hydrophobic residues are all in proximity
to each other. With this study, we have gained an insight into
two peptides derived from HGF K1, H-RN, which was shown
to  inhibit  angiogenesis  effectively,  does  have  more
hydrophobic  residues  than  H-FT,  which  was  inactive  in
antiangiogenesis. In addition, the hydrophobic residues in the
H-RN sequence were much more in proximity to each other
than those in H-FT sequence. This was in accordance with
Mayo’s discovery, and also provides additional evidence for
the  phenomenon  that  proximal  hydrophobic  residues  are
relatively commonly seen in peptides with antiangiogenic
activity.
RF/6A, which is a choroid-retinal endothelial cell line, is
widely  used  for  in  vitro  studies  on  retinal  and  choroidal
neovascularization [56,64]. As was shown in this study, H-
RN  could  effectively  inhibit  RF/6A  cell  proliferation,
migration, and tube formation, which indicates its potential
for inhibiting retinal and choroidal neovascularization. This
was demonstrated by in vivo retinal neovascularization in the
mouse  model  of  OIR.  VEGFab  is  a  neutralizing  VEGF
antibody that can block the bioactivity of mouse VEGF. The
reason we chose VEGFab instead of bevacizumab to be a
positive  control  in  the  OIR  mouse  model  was  that
bevacizumab is a humanized variant of the antihuman VEGF
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1989Figure 4. H-RN inhibits angiogenesis of chorioallantoic membrane model. A-D: Representative photographs of antiangiogenesis in chick
chorioallantoic membrane (CAM) of H-RN, H-FT, and scrambled peptide. Filter paper disks saturated with H-RN (10 µg, 50 µg), H-FT (10
µg, 50 µg), scrambled peptide (10 µg, 50 µg) or PBS were placed on the CAMs for 72 h of incubation. Vessels around the filter disks were
photographed: A, Control (PBS); B, 50 µg H-RN per egg; C, 50 µg H-FT per egg; D, 50 µg scrambled peptide per egg. (magnification was
×11.5).  E:  Quantitative  results  showed  different  effects  of  two  peptides  on  CAM  angiogenesis.  H-RN  inhibited  CAM  angiogenesis
significantly, compared to the PBS group. No such antiangiogenesis activity of H-FT or scrambled peptide was found (** p<0.01, each
condition versus control).
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1990Figure 5. H-RN inhibits retinal neovascularization. A: Retinal vascular distribution of a normal pup raised in room air. B: This figure shows
a representative retina from 17-day-old pups that were subjected to 5 days of 75% oxygen tension and then maintained in room air for an
additional 5 days. Circles indicate the neovascular tufts. C: A retina from a mouse pup injected with vascular endothelial growth factor ab
(VEGFab; 50 ng/µl). D: A retina from a mouse pup injected with H-RN (50 mM). E: A retina from a mouse pup injected with H-FT (50 mM).
F: A retina from a mouse pup injected with scrambled peptide (50 mM, magnification, ×40). G: A hematoxylin- and eosin-stained section of
P17 control raised in room air. H: P17 retina exposed to hyperoxia from P7 to P12, and returned to room air from P12 to P17. Arrows indicate
neovascular tufts extending into the vitreous. I: A section from 50 ng/µl VEGFab-treated hyperoxia group. J: A section from 50 mM H-RN-
treated hyperoxia group. The retina of I and J presented obvious reduced abnormal neovascularization tufts (arrows). K: A section from 50
mM H-FT-treated hyperoxia group. L: A section from 50 mM scrambled peptide treated hyperoxia group (magnification, ×400). M:
Quantification of neovascular lumens response to hyperoxia. Lumens extending from the internal limiting membrane into the vitreous were
counted. Data in each column present means±SD values of total number of vascular lumens per retinal cross-section, from 7 to 9 eyes of 7–
9 mice. Note that the lumens in VEGFab and H-RN-treated group are reduced significantly more than the control and PBS groups (p<0.001),
while the number of lumens in the H-FT and scrambled peptide-treated group had no difference from the control and PBS treated group
(p>0.05). These experiments were repeated three times with similar results (** p<0.01, each condition versus control).
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1991mAb. It has been characterized as species-specific, and has
little or no interaction with murine VEGF [65].
In this 17-day model, treatment with H-RN of different
concentrations on day 12 and day 14 controlled the degree of
blood vessel tuft formation and blood vessel tortuosity, though
not as effectively as did VEGFab. Even at 10 mM, H-RN
appeared to be an active inhibitor of neovacularization in OIR,
which inhibited neovascular lumens by 50%. Furthermore,
this peptide improved retinopathy by abrogating the invasion
of new vessels beyond the inner-limiting membrane of the
retina, according to the analysis of eye sections. The CAM
model is widely used to study angiogenic phenomena because
of its easy access to the blood vessel network, its function in
low  immunocompetence,  and  the  time  of  this  assay  is
relatively short [66]. In the present study, H-RN was found to
effectively  inhibit  CAM  angiogenesis.  This  might  be
considered a sign of the possible antiangiogenic activity of H-
RN in other cases of neovascularization. We may investigate
this in further studies.
H-RN  demonstrated  significant  stability  in  different
aqueous solutions. After 48 h of incubation in 37 °C solutions,
less than 5% of the H-RN degraded. It was even more stable
than an acylated 28-amino acid peptide described by Staes et
al. [54]. BSS PLUS™ has no components foreign to the eye
and no pharmacological action. It contains the appropriate
bicarbonate,  pH,  and  ionic  composition  necessary  for  the
maintenance of normal retinal electrical activity. This is why
it was chosen as a test solution in the stability assay. However,
the  actual  intraocular  condition  is  more  complicated,
including  various  proteases,  inflammatory  cells,  and
cytokines  caused  by  an  injection  procedure  or
neovascularization disease. Hence, further investigation of H-
RN stability in vivo is needed in the future.
A key finding in this study is that H-RN is a newly
discovered  peptide  derived  from  HGF.  Its  antiangiogenic
activity  is  not  as  strong  as  that  of  VEGF-neutralizing
antibodies, but it is easy and inexpensive to synthesize, and it
possesses the other advantages of small peptides described
above. However, there are still some limitations to the use of
peptides as drugs. They have a short half-life and low stability
in vivo, due to their degradation by proteases. There are some
other  disadvantages  of  large  peptides,  such  as  immune
response induction, poor bioavailability, limited delivery by
injection, though small peptides that have fewer than 20 amino
acids could have those effects to a less degree [21].
H-RN is a small peptide with 11 amino acids. In the OIR
model,  its  effective  concentration  reached  the  millimolar
scale, and reinjection problems could exist in future research.
Some chemical modifications would be helpful for increasing
its half-life, such as substituting D-amino acids for L-amino
acids, cyclization, substitution by noncoded amino acids, end
modifications, and modification of peptide side chain. The
addition of sugars or salts, as well as heparin, can enhance the
thermal  stability  of  peptides,  cause  self-association,  and
modulate solubility. Non-ionic surfactants stabilize peptides
against  self-aggregation.  Cationic  and  anionic  surfactants
facilitate absorption of peptides across biologic membranes.
Protease inhibitors, such as sodium glycocholate, can also be
coadministered with the therapeutic agent. New drug delivery
systems, such as intravitreal slow-release delivery systems,
should  be  developed  to  achieve  an  effective  drug
concentration in the retina or choroidal tissues [67]. These
efforts might help decrease the necessary concentration of H-
RN.
In the present study, all the above experiments primarily
demonstrated the antiangiogenic activity of H-RN. In future
studies,  we  will  investigate  the  pharmacodynamics  and
pharmacokinetics of H-RN, modified synthetic H-RN with
improved pharmacodynamics and pharmacokinetics, the use
of  endothelial  cell-specific  cell  penetrating  peptides,  the
controlled-release carrier or lentiviral vector as drug carriers,
and novel delivery methods, as described in a review paper
[68]. These works will promote the development of novel
peptide drugs and clinical applications.
From  the  lines  of  evidence  described  above,  a  new
peptide derived from HGF was shown to have antiangiogenic
activity in a choroid-retinal endothelial cell line, in the chick
chorioallantoic membrane, and in a mouse model of oxygen-
induced  retinopathy.  Retinal  and  choroidal
neovascularization  occurring  as  a  severe  complication  of
diabetes mellitus, as age-related macular degeneration, and as
ROP  can  cause  vision  impairment  and  blindness.  The
identification of novel small peptides such as H-RN that can
effectively inhibit retinal neovascularization may lead to new
potential  drug  discoveries  and  the  development  of  new
treatments for pathological retinal angiogenesis.
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